Background: Arrhythmia is the foremost cause of sudden death after myocardial infarction (MI). Animal models have recently shown that erythropoietin (EPO) can reduce the incidence of arrhythmia after MI.
INTRODUCTION
Being the prime cause of sudden cardiac death, arrhythmia is defined as irregularity in electrical activity and rhythmic beating of the heart. Arrhythmia occurs in approximately 70% of patients after myocardial infarction (MI). 1 Life-threatening ventricular tachyarrhythmias occur during first 24-48 hours of MI. 2 Additionally, preventing arrhythmias has been shown to decrease mortality and cardiac death. 3, 4 Numerous studies have been designed to verify the efficacy of device-based therapies, catheter-and surgery-based interventions, or electrophysiological testing. 1, 5, 6 Therefore, an investigation into the proper medication for reducing arrhythmias after MI is required.
There is promising evidence that erythropoietin (EPO) may prevent arrhythmias in the ischemic heart. 7, 8 EPO is a renal hormone secreted in response to hypoxia with an essential role in regulating plasma hemoglobin concentrations. 9 In addition to hematopoiesis effect, a considerable body of data supports pleiotropic effects of EPO including cardioprotection due to reduction in size of the infarct and improvement in left ventricular (LV) function. [10] [11] [12] Such effects are mainly mediated by inhibiting apoptosis, mobilizing endothelial progenitor cells, inhibiting migration of inflammatory cells, and promoting angiogenesis. 9 Although cardioprotective effects of high doses of recombinant human EPO (rh-EPO) have been investigated in ischemia/reperfusion injury in human, studies about its effects on lethal arrhythmias are limited to a few animal models. [13] [14] [15] [16] These research have shown that administration of EPO immediately before reperfusion can significantly reduce the incidence of ventricular fibrillation (VF) in animal models. 7, 8 As mentioned above, the effects of rh-EPO on arrhythmias in human remain unidentified. This study is the first research evaluating the effects of administration of high-dose rh-EPO on the incidence of arrhythmias in patients with ST-elevation MI (STEMI) after successful primary percutaneous coronary intervention (PCI).
MATERIALS AND METHODS

Study Population
The study was conducted in the Cardiology Department of Ghaem Educational, Research and Treatment Center, Mashhad, Iran, from October 2013 to March 2014. One hundred patients with ST-elevation acute MI (AMI) were screened for inclusion in the study (Table 1) , and finally 40 patients were randomized by www.randomizer.org to receive either placebo (n = 20) or EPO (n = 20) and entered this doubleblind, placebo-controlled randomized trial (Fig. 1) . This study was approved by the Ethics Review Boards of Mashhad University of Medical Science. All patients participated in the study after signing a written informed consent.
AMI was defined as experiencing severe chest pain for .30 minutes, ST elevations in electrocardiogram ($2 mm in precordial leads and $1 mm in limb leads), and elevated serum levels of cardiac enzymes (creatine kinase-MB and troponin I).
Study Design
Subsequent to primary PCI, patients were randomized into EPO and placebo groups. The EPO group received 33,000 units of rh-EPO (PDpoetin; Pooyesh Daru Co) immediately after PCI that had been infused with 50 mL isotonic solution of sodium chloride for 30 minutes. A volume of 50 mL sodium chloride was administered to the placebo group.
Creatine kinase-MB (CK-MB) levels and ST-elevation resolution were evaluated as ischemic parameters. The resolution for the sum of ST-segment elevation [sum STR (ST resolution)] following 60 minutes of primary PCI in addition to biochemical markers was considered to verify the prognostic value of these indices in patients with STEMI.
The sum STR is depicted as percentage from the baseline.
STR percentage ¼ Sum of STR before PCI 2 Sum of STR after PCI Sum of STR before PCI · 100:
CK-MB was assessed 3, 12, and 24 hours after PCI. 17, 18 Arrhythmias were blindly documented by full 12-lead configuration 24 hours after PCI by a cardiologist who judged arrhythmia development, and diagnosis was unaware of the patient's clinical information. Significant arrhythmias after STEMI were categorized as follows: nonsustained ventricular tachycardia (VT), sustained VT, and VF ( Table 2 ). All arrhythmias were filed in Nihon Kohden Cardiofax C Model-1150, and afterward, the type, duration, and the frequency in which they occurred were analyzed.
To assess the hemodynamic effects of EPO, blood pressure and heart rate were continuously recorded once before PCI and subsequently 3, 6, 12, 24, and 48 hours and then 7 and 14 days after PCI. Patients with systolic blood pressure below 80 mm Hg and heart rate above 100/min had hemodynamic disturbances. Patients with systolic blood pressure $160 had significant hypertension. Blood samples were collected before PCI and then 24 and 48 hours and 14 days after PCI to quantify blood cell count, hemoglobin, and hematocrit levels. Levels of potassium, sodium, and serum creatinine were adjusted before PCI in the 2 groups.
Coronary Angiography, Primary PCI, and Medical Treatments A standard coronary angiography was performed in all patients followed by stenting 6 ballooning primary PCI, and reperfusion was achieved in all patients with Thrombolysis in MI score 3 within the first hour after AMI. Throughout the PCI, 100 U/kg bolus of heparin was administrated to each patient. After angioplasty, 600 mg of clopidogrel and 300 mg of aspirin were administered to patients as a loading dose followed by 75 and 80 mg/d of clopidogrel and aspirin, respectively. Beta-blockers, statins, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors were prescribed according to referrals' orders.
Statistical Analysis
Descriptive statistics are presented as mean 6 SD for continuous variables, whereas absolute frequencies are shown for categorical data. Baseline characteristics of patients between the 2 groups were compared using independent t test (continuous variables), and x 2 was applied for evaluating categorical data. One-way and 2-way repeated measure tests were used to estimate the treatment effects and calculate the intragroup and intergroup differences (2 sides and P , 0.05). SPSS 16 (SPSS, Inc, Chicago, IL) was used to perform all statistical analyses.
RESULTS
Baseline Characteristics of Patients
Forty patients were randomly divided into EPO and placebo groups (20 patients in EPO group and 20 patients in placebo group). In the each group, 14 patients had anterior MI and 6 patients had inferior posterior right ventricular MI. A comparison was made between demographic characterizations (age, body mass index, and sex) and cardiovascular risk factors (smoking, hypertension, hyperlipidemia, and diabetes mellitus). No significant differences were observed between the groups. Moreover, there were no significant differences between the baseline level of sodium, potassium, and blood urea nitrogen between the 2 groups ( Table 3) .
Evaluation of Anti-ischemic Effects
A comparison made between percentage of STR in the 2 groups did not show any significant differences (EPO group = 82.72% 6 12.84%, placebo group = 78.68% 6 35.78%, P = 0.650).
There were no significant differences between levels of CK-MB in the 2 groups during 24 hours (P = 0.186) (Fig. 2) . Figure 3 shows all arrhythmias that occurred in our patients; 75% of patients had normal sinus rhythm during the first 24 hours following PCI. The most frequent arrhythmia was nonsustained VT (20% of all arrhythmias), and VT and VF had minor incident (5%) (Fig. 3) .
Comparing the Incidence of Arrhythmias Between the 2 Groups
Comparison of the occurrence of arrhythmias between the 2 groups showed significant differences (20% in EPO group and 35% in placebo group, P = 0.043). When the occurrence of nonsustained VT (EPO = 20% and placebo = 25%, P = 0.112), sustained VT (there was no VT in EPO group and placebo = 5%, P = 0.499), and VF (there was no VF in EPO group and placebo = 5%, P = 0.499) was compared, no significant differences between the groups were observed.
Hematologic and Hemodynamic Evaluations
RBC, WBC, and platelet counts did not show any significant differences between the 2 groups before PCI. The differences remained nonsignificant 24 and 48 hours after PCI. Hematocrit and hemoglobin levels were within normal ranges, and there were no significant differences between the 2 groups after 14 days (Table 4) . Evaluation of systolic and diastolic blood pressures and heart rate among the 2 groups did not show any significant differences before PCI and a week after PCI (Table 5) . Moreover, there were no significant hypertension (SBP $ 160 mm Hg) and hemodynamic disturbances (systolic blood pressure [SBP] ,80 mm Hg and heart rate [HR] .100/min) in the EPO group before and after PCI.
DISCUSSION
This is the first study to demonstrate that the administration of rh-EPO after PCI significantly reduces the occurrence of arrhythmias in patients with STEMI. Investigations have shown that 90% of VT and VF events occur within the first 48 hours after PCI. Not being benign, such arrhythmias result in a considerable increase in morbidity and mortality rate of patients undergoing primary PCI. 20 In previous studies, using both EPO and darbepoetin revealed that erythropoietin-stimulating agents with a higher first dose (.20,000 IU) or total dose ($30,000 IU) improved LV ejection fraction more significantly when compared with that of lower doses (,20,000 IU). 21 High-dose EPO was superior to placebo, statistically improving LV ejection fraction by 1.02% and LV end systolic volume by 24.61 mL in patients with acute STEMI, and it was generally well tolerated. The adverse effects reported in patients receiving high-dose EPO were essentially consistent with those in the placebo group. Therefore, in this study, we administered the dose of 33,000 IU of EPO. 22 In the clinical setting for patients, episodes of ventricular arrhythmias arose and continued for 12-48 hours after the onset of MI. 23 In this study, occurrence of arrhythmias was monitored for 24 hours after PCI, and results showed significant differences in this regard. Burger et al 8 suggested beneficial effects of pretreatment with EPO on high-risk patients; although, treatment in the sufferers of coronary artery occlusions usually starts after the onset of symptoms.
The role of EPO in the protection of the heart from injury has been studied extensively in animal models, and it is increasingly becoming obvious that EPO provides significant protection against cell death and cardiac dysfunction. [10] [11] [12] 24, 25 In rodent models, EPO has been reported to decrease mortality. 26 Nevertheless, the controversy about administration of EPO continues in human studies. Nakamura et al 14 demonstrated that short-term therapy with low-dose rh-EPO could improve LV function and decrease the size of infarct with no noticeable effects on neointimal hyperplasia in PCI-treated coronary arteries. Ferrario et al 27 showed that administration of short-term high-dose EPO in the early phase of PCI-treated AMI could ameliorate LV function and diminish the size of infarct, while hemoglobin and hematocrit values remained normal. However, In REVEAL administration of 60,000 IU rh-EPO after PCI in patients with STEMI was successful neither in the reduction of the size of MI nor in attenuation of cardiac remodeling. 28 Similarly, a study on patients with non-ST-elevation acute coronary syndromes receiving a single bolus of rh-a-EPO did not show any positive clinical effects or changes in cardiac enzymes levels. Despite numerous research, the effects of EPO on the human cardiac electrophysiology have remained unidentified thus far. 29 This study demonstrated that administration of high-dose rh-EPO after PCI can significantly reduce arrhythmias in patients with STEMI, and when types of arrhythmias were analyzed, the incidence of significant arrhythmias in the placebo group was more than 2-fold in comparison with the EPO group. Such finding is in agreement with the initial observations of Hirata et al, 7 who detected PI3-kinase-dependent reductions in VF after myocardial ischemic/reperfusion in dogs, and that of Burger et al 8 who demonstrated EPO-mediated reductions in ventricular arrhythmia through increased expression of neuronal nitric oxide synthase (nNOS) in cardiomyocytes during myocardial ischemic/reperfusion in mice. Another research on rats showed that a single bolus dose of 5000 U/kg EPO at the time of resuscitation from VF could maintain the hemodynamic efficacy of chest compression and enable the return of spontaneous circulation with greater aortic pressure. 30 As shown in animal models, antiarrhythmic effects of rh-EPO are applied through PI3-kinase-dependent pathways and through several plausible mechanisms. First, on reperfusion conditions, activation of phospholipase C (PLC) through membrane a-adrenoreceptors of the myocardial cells augments the production of inositol-1,4,5-trisphospate (IP3), which in turn triggers IP3 receptors on sarcoplasmic reticulum and releases Ca 2+ . An elevation of the intracellular Ca 2+ levels initiates slow Ca 2+ oscillations that lead to a delayed afterdepolarization, generating many arrhythmias such as VF. Moreover, PLC hydrolyzes phosphatidylinositol-4,5-bisphospate (PIP2) to form IP3. Given that PIP2 is a similar substrate for PI3-kinase and PLC, rh-EPO may prevent lethal arrhythmias through activation of PI3-kinase pathways that decreases PIP2 levels and results in the inhibition of Ca 2+ overload by IP3.
Second, oxygen-derived free radicals participate in the creation of reperfusion arrhythmias; therefore, rh-EPO may decrease reperfusion arrhythmias through averting the release of free radicals from neutrophils or act as a radical scavenger. 7 The third mechanism for antiarrhythmic effects of EPO is possible augmentation in nNOS. Burger et al 8 declared that the EPO-mediated declines in arrhythmias were probably in part mediated by nNOS, as there were not any noticeable antiarrhythmic effects subsequent to treating nNOS (2/2) mice with EPO.
Finally, pervious researchers have found evidence for antiarrhythmic effects of EPO that is possibly attributable to decrease in the size of myocardial infarct. Our findings were in accordance with that of Burger et al and showed that antiarrhythmic effects of EPO were not related to its antiischemic effects; because, in our study, the ischemic factors (CK-MB and STR percentage) had no significant changes, whereas the occurrence of arrhythmias was significantly decreased in the EPO group.
There are some concerns about the safety of administration when high doses of EPO are used. Some of the reported adverse effects for EPO are as follows: hypertension, seizure, elevated hematocrit and hemoglobin levels, and potential thrombogenic and carcinogenic effects. 31, 22 Moreover, EPO can enhance the formation and reactivity of the platelets and red blood cells. 32, 33 In this study, levels of hematocrit and hemoglobin remained within normal ranges after 2 weeks of administration. There were no significant differences in systolic and diastolic blood pressures and heart rate between the 2 groups within 2 weeks. Therefore, it seems that administration of EPO with this dose can be considered safe in patients with STEMI. In other studies, however, EPO has been administered with a dose of nearly twice more than 33,000 IU, and no adverse effects have reported. 34, 35 As a limitation, this investigation was a pilot study examining a small population of patient; therefore, the authors suggest the aforementioned results be considered cautiously.
This study demonstrated that treatment with EPO could reduce the incidence of significant arrhythmias after PCI in patients with STEMI. Although, our findings require a comprehensive investigation in order to be translated into clinical practice, they may support the use of rh-EPO as a cardioprotective agent in the treatment of patients with MI. 
